Blog

The International Symposium is the largest medical and scientific conference on ALS/MND in the world. It is the premier event in the ALS/MND research calendar breaking records once again at the end of 2017 with over 1200 delegates from 40 countries demonstrating the energy and dynamism of the global ALS/MND research community. Here is an update on Symposium happenings and news from Carol Birks, CEO, MND Australia.

"Over the three-day event the concurrent scientific and clinical sessions

The Allied Professionals Forum enables the sharing of ALS/MND care and support innovations to help guide practice worldwide. Over 250 delegates attended 15th Annual Allied Professionals Forum, Boston, in December 2017 to hear 16 presentations covering a wide variety of topics  on resource development, carer and family support, cannabis use, respiratory care and innovative approaches to assistive technology provision. You can watch

From 8 to 10 December 2017, ALS/MND researchers, advocates and people living with ALS/MND from across the world, flew into Boston, USA to learn about and discuss the most recent developments in ALS/MND research at the 28^th International Symposium on ALS/MND. You can watch the recap

An Australian trial of the drug Tecfidera for MND was reported in 'The Age' newspaper on 21 December. The Australian TEALS (Tecfidera in amyotrophic lateral sclerosis) study is a multi-centre Phase 2 clinical trial to investigate the safety, tolerability and effectiveness of a drug called Tecfidera in people with MND. Tecfidera is currently used to treat relapsing multiple sclerosis (MS) in Australia by slowing down the progression of physical disability of MS.

Thank you to Nick Moretti from the Newcastle Italian Film Festival for your continued support and donation of $15,000. This is the fourth year that MND NSW has been supported by the festival. Pictured is Nick Moretti (left) and Graham Opie, CEO MND NSW.